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Abstract
Vast emerging evidences are linking the base modifications and gene expression involved 
in essential metabolic pathways. Among the base modification markers extensively stud-
ied, 5-methylcytosine (5mC) and its oxidative derivatives (5-hydroxymethylcytosine 
(5-hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC)) dynamically occur 
in DNA and RNA and have been acknowledged as the important epigenetic markers 
involved in regulation of cellular biological processes. The modification of C has been 
characterized biochemically, molecularly, and phenotypically, including elucidation 
of its methyltransferase complexes (writer), demethylases (eraser), 10-11 translocation 
proteins (TETs), and direct interaction proteins (readers). The levels and the landscapes 
of these epigenetic markers in the epitranscriptomes and epigenomes are precisely 
and dynamically regulated by the fine-tuned coordination of the writers and erasers 
in accordance with stages of the growth, development, and reproduction as naturally 
programmed during the life span. In mammalian genome, the TET family is consisted of 
three members, including TET1, TET2, and TET3. The link between aberrant modifica-
tions and diseases, such as cancers, neurodegenerative disorders, and heart diseases, has 
been appreciated. This review article will highlight the research advances in the writers 
and erasers for the modifications of cytosine in genome, as well as the dual function of 
TET1 in tumorigenesis as a tumor suppressor and a promoter. Additionally, the future 
research directions are addressed.
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1. Introduction
Epigenetics is defined as the investigation on gene expression alterations heritable to next gen-
erations caused by nongenetic but heritable cellular memory other than DNA sequence varia-
tions [1]. The epigenetic memories including dynamic base modifications (DNA methylation/
demethylation), histone modifications, chromatin architecture, and noncoding RNAs main-
tain all the biological processes in the programmed tracks. Any aberrant alterations could lead 
to development of abnormality and initiation of diseases such as neurological disorders and 
cancers as reviewed in [2–8]. A micro-event in base modification could lead to strong “earth-
quake” in the signaling pathways and the consequent alteration of organism phenotypes, even 
diseases. The most extensively studied modifications are methylation and demethylation of 
5-cytosine (5-C).
DNA base modifications such as methylation of 5-mC [9–14] and 5-hydroxymethylcytosine 
(5-hmC) [15–21] have been acknowledged as the best characterized epigenetic markers in 
mammalian brains [20, 22–24] and ES cells [25–27], essentially regulating chromatin struc-
ture and consequently gene expression with the potential mechanisms. This review article 
mainly focuses on the recent advances in methylation/demethylation modifications of 5-C in 
mammalian genomes, including methylation/demethylation machineries, methyltransferase 
complexes (writers) and demethylase complexes (erasers), as well as the distinct functions of 
TET1 in the regulation of tumorigenesis.
2. Cytosine modifications
To maintain the normal life process, any base modification must be dynamically and tightly 
regulated in accordance with stages of the growth, development, and reproduction, includ-
ing modification generation by methyltransferase complexes (writers), removal by demethyl-
transferases (erasers), as well as the preferential binding protein components (readers), to get 
the related epigenetic markers into the biochemical effects.
2.1. Methyltransferases of cytosine methylation
DNA methylation, particularly the most abundant CpG methylation marker 5-mC, is an essen-
tial modification of DNA in the mammalian genome, typically linked with gene silencing and 
involved in gene regulation, development, genome defense, and disease. A family of DNA 
methyltransferases named (DNMTs) is responsible for the addition of methyl groups to the 
5-position of the carbon, including DNMT1, DNMT2, DNMT3a, DNMT3b, and DNMT3L. The 
five members are structurally and functionally distinct. The three methyltransferase enzymes 
DNMT1, DNMT3a, and DNMT3b serve as writers for the de novo CpG methylation pattern 
during embryogenesis [28, 29], while DNMT1 could confer the maintenance of parent DNA 
methylation patterns to the new daughter strand DNA during DNA replication [30].
Traditionally, DNMT1 was regarded as the maintenance methyltransferase copying methyla-
tion marks of hemimethylated DNA to the newly synthesized daughter strand during DNA 
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replication, making the enzyme indispensable for dividing progenitor cells [29, 39, 40]. This is 
supported by the finding that DNMT1 has higher affinity to hemimethylated DNA [41, 42] and 
that gene knockout of Dnmt1 in the central nervous system leads to lethal in mice [43]. While 
Dnmt1 deletion in all dividing somatic cells is also lethal [43–47], mouse embryonic stem 
cells are viable, despite the resulting global loss of DNA methylation [48]. Notably, human 
embryonic stem cells (ESCs) also displayed a global demethylation upon Dnmt1 deletion [49].
However, in accordance with the special requirement, the DNMT1 and DNMT3A are function-
ally correlated. For example, in the adult brain, both methyltransferases could carry out cytosine 
methylation in the promoter and gene body regions, leading to transcription repression [31].
While DNMT1 is believed to function mainly for the maintenance of established patterns of 
DNA methylation in normal living cells, in the diseased cells such as cancer cells, DNMT1 
alone is not sufficient to maintain the programmed normal gene hypermethylation. As such, 
the collaboration of DNMT1 and DNMT3b is indispensable for the maintenance function.
Dnmt3l is believed to function as a stimulator of the Dnmt3A and Dnmt3B, and has related 
function with DNMT2 [32, 36–38].
Sirt1 regulates DNA methylation and differentiation potential of embryonic stem cells by 
antagonizing Dnmt3l. DNMT2, a tRNA methyltransferase and the most conserved member 
of the DNMTs methylates tRNAs to protect them from ribonuclease digestion. More impor-
tantly, DNMT2 is functionally related to the sperm small RNA (sncRNAs) mediated essen-
tially in writing the “paternal epigenetic signature” to sperm RNA [32]. The mechanism is 
that the DNMT2-conferred m5C in sncRNAs regulates the secondary structure and biological 
properties of sncRNAs, suggesting that sperm RNA modifications could serve as one of the 
carriers for paternally imprinted epigenetic memories [33].
Coordination of the DNA methylation by DNMTs as well as histone modifications contributes 
to the regulation of cell death through development, aging, and disease [34, 35].
2.2. Demethylation and demethylases
The dynamic DNA methylation/demethylation is tightly regulated during the whole life span. 
DNA demethylation, the removal of a methyl group, is not just a reverse process of methyla-
tion, but rather very complicated metabolic pathways indispensable for reactivation of genes and 
directly involved in pathogenesis of diseases such as cancers and neurological disorders. Either 
passive, active, or combination of both, leads to demethylation of DNA. The passive mechanism 
renders the automatic demethylation in a way that dilution and gradual loss of methylation in 
the newly synthesized DNA strands during successive replication rounds. In contrast, the active 
demethylation is believed to be the most important mechanism for active DNA demethylation via 
5-mC oxidation catalyzed by the 10-11 translocation proteins (TETs) in alpha-ketoglutarate (a-KG) 
and Fe(II) dependent manner [22]. In addition to TETs, several other enzymes are acknowledged 
to be involved in the active mechanisms for demethylation, such as activation-induced cytidine 
deaminase (AID) [50], TET [51, 52], and thymine DNA glycosylase (TDG) [53–55].
5-hmC is generated by oxidation of 5-mC by TET, and the 5-hmC faces several fates once it is 
generated. First, the 5-hmC could be directly converted to regular cytosine through mechanisms 
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involving the base excision repair pathway. Second, stepwise, a small percentage (~10%) of 
the 5-hmC is converted to 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), respectively 
[56, 57]. The 5-fC and 5-caC are finally converted into regular cytosine [58] with the help of 
Thymine-DNA glycosylase (TDG). Finally, in some tissues such as stem cells and adult neuron 
cells, high 5-hmC levels could be detected particularly in transcribed regions adjacent to the 
promoter and enhancers, positively correlating with gene expression. The low turnover rates 
of 5-hmC in some tissues suggest that besides serving as an intermediate of active demeth-
ylation, the stable accumulation of the 5-hmC forms a dynamic 5-hmC landscape to serve as 
special epigenetic markers, potentially altering the local chromatin structures via recruiting 
or repelling some special protein components with high affinity to or low even repellent to 
5-hmC-harboring DNA [59, 60]. For example, 5-hmC loss has become a hall marker for cancer 
cells [61–66]. In addition, the TET members are acknowledged as the tumor suppressors as Tet 
gene mutations or deletions have been identified in some tumor tissues [67].
In mammalian genome, the TET family is consisted of three members, including TET1, TET2, 
and TET3. While all three TET members could function as hydroxylases for conversion of 
5-mC to 5-hmC and further stepwise from 5-hmC to 5-fC and 5-fC to 5-caC, their functions 
involved in diverse biological pathways are in the development stage and specifically in 
tissue-dependent manners [25, 68].
2.2.1. TET1 and regulation of its target gene expression
Highly expressed in ESCs, PGCs, and inner cell mass of blastocyst, TET1 protein has been proven 
to be mainly responsible for the initial oxidation of 5-mC to 5-hmC, and to establish the para-
doxically dual distinct epigenetic patterns in transcriptional activation and repression in accor-
dance with life processes of growth and development. Alternative splicing mechanism leads 
to several TET1 isoforms, including the full-length canonical and the short transcripts [69–73]. 
TET1 expression is regulated by very complicated factors including the reprogramming factors 
such as Oct3/4, Nanog, and Myc [68, 70] in early embryos, ESCs and PGCs [69], the transcription 
factors in the differentiated cells, and STAT3/STAT5 in acute myeloid leukemia (AML) [74].
The full length of TET1 protein is believed to have multiple functions in regulation of gene 
expression. In general, TET1 catalyzes the oxidation of 5-mC to 5-hmC, which serves as an epi-
genetic marker and intermediate for active demethylation, leading to transcription activation. 
The more emerging evidence has supported the TET1 conferred transcription activation and 
repression of its direct target genes [75–77] at the transcriptional level. At the molecular level, 
the interaction between TET1 and SIN3a facilitates transcription activation of their target genes 
at the transcription level. More importantly, the interaction has been detected between TET1/
TET2 and E26 transformation-specific or E-twenty-six (ETS) family, one of the largest transcrip-
tion factor families. For example, ETS variant 2 (ETV2), an ETS family transcription factor, 
interacts with TET1/TET2 to recruit the demethylases to the Robo4 promoter for demethylation-
mediated transcription activation during endothelial differentiation. More recently, the Methyl-
CpG-binding domain (MBD) protein, such as MBD1, through its CXXC domain recruits TET1 
other than TET2 and TET3 to the heterochromatin for oxidation of 5-mC to 5-hmC, whereas the 
resulting 5-hmC releases the MBD1 from the binding sites by affinity-based displacement [78].
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On the other hand, TET1 also confers transcription repression of its target genes. It is accepted 
that the TET1-mediated transcription repression does not require the catalytic activity of the 
TET1 in conversion of 5-mC to 5-hmC, but rather the interaction between TET1 and some 
other protein components that contain repressor complexes [79]. Several mechanisms for 
TET1-mediated transcription repression have been proposed. First of all, TET1 binds a large 
number of polycomb target genes and interacts with SIN3A, the core component of the SIN3A 
co-repressor complex, leading to the transcription repression of their co-target genes via the 
SIN3A conferred histone deacetylation [76, 80].
The second mechanism of the TET1 conferred transcription repression is involved in TET1 
interaction with recruitment of MBD repression complexes such as MBD3 [78, 81] at least in 
ES cells. The evidence of the mechanism includes the co-localization of TET1 and MBD3 in 
ESCs, higher affinity to 5-hmC than 5-mC, and association of the MBD3 knockdown with 
reduced level of 5-hmC as well as the enhanced expression of the 5-hmC-modified genes.
Several other mechanisms that TET1 represses the transcription have been also uncovered. It 
is convinced that TET1 is involved in the repression of polycomb-targeted regulator genes in 
accordance with the development stage by recruiting polycomb repressive complex 2 (PRC2) 
to the CpG-rich promoters of these genes [82]. Further study indicated requirement of the 
catalytic activity in oxidation of 5-mC to 5-hmC for the PRC repressive complex-mediated 
repression, evidenced by the fact that the PRC2 was co-localized with 5-hmC [80], while TET1 
recruits the EZH2 DNMT-containing PRC complex targeting H3K27 methylation.
During the early stages of epiblast differentiation, repression of TET1 target genes was 
conferred by the interaction between TET1 and the JMJD8 and enhancement of the JMJD8 
demethylase transcriptional repressor expression [83], but does not require the TET1 oxidation 
activity. Although TET1, TET2, and TET3 are all expressed in gonadotrope-precursor cells, the 
TET1 expression was dramatically decreased in the differentiated cells. Differentiation with 
according increase in the expression of the luteinizing hormone gene (Lhb). The short iso-
form of TET1 with deletion of the N-terminal CXXC-domain binds the H3K27me2/3 enriched 
region located at the upstream promoter of the Lhb gene, downregulating its expression and 
leading to differentiation deficiency [73].
3. Distinct functions of TET1 on tumorigenesis
3.1. Tet1 functions as an oncogene in some cancers
Initially, given the mutations and the deletions as predominant variation of TET proteins, par-
ticularly TET1, in human cancer genomes, it was accepted that TET1 functions as a tumor sup-
pressor [61, 65, 66]. Indeed, TET1 and TET3 bear the predominant mutations in some tumors 
including colorectal cancer, melanoma, and cutaneous squamous cell carcinoma [88–90]. 
However, emerging evidences are connecting the TET1 overexpression and tumorigenesis as 
well, most likely attributed to activation of cancer-specific oncogenic pathways mediated by 
TET1 conferred hypomethylation [72, 84] (Figures 1 and 2).
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Figure 2. Sequestration of miR-26 by its target 3’UTRs of Tet1 leads to miR-26 deficiency to target its target Ezh2, an 
oncogene. (A) In normal cells, due to low level of Tet1 expression, majority of the miR-26 targets to Ezh2 leads to 
sufficient silencing of the oncogene. (B) In some cancer cells, dramatically enhanced transcription of Tet1 sequestrates 
the miR-26, conferring the miR-26 deficiency to target its Ezh2 target 3’UTRs. Consequently, miR-26 deficiency to the 
Ezh2 releases the miRNA-mediated expression repression of the oncogenes, conferring the initiation of tumorigenesis.
Figure 1. TET1 functions as a tumor promoter by activation of the oncogenes via demethylation of the methylated 
promoter regions in the oncogenes. (A) In normal cells, the promoter regions of the oncogenes are usually methylated 
and therefore silenced. (B) However, in some cells, TET1 is highly expressed and recruited by its interaction partners 
to the methylated promoter regions of the oncogenes, leading to demethylation and the activation of the oncogenes. 
Consequently, the oncoproteins initiate tumorigenesis.
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3.1.1. TET1 demethylation associated activation of the members in the oncogenic pathways
TET1 overexpression accounts for about 40% of patients with triple-negative breast cancer 
(TNBC) that belongs to the most hypomethylated cancers observed, leading to about 10% 
hypomethylation of the queried CGI and activation of oncogenic pathways including PI3K, 
EGFR, and PDGF. Thus, TET1 seems functioning as a potential oncogene and could serve 
as a target for intervention therapy [84]. This phenomenon was observed not only in NTBC, 
but also in MLL-rearranged leukemia where TET1 is believed to activate the downstream 
oncogenic pathways by its demethylase activity, serving as an oncogene [86]. Additionally, 
via DNA hypomethylation, TET1 was demonstrated to regulate the expression of MUC4, one 
member of the mucin (MUC) family and an essential factor for carcinogenesis and tumor 
invasion in lung neoplasms, functioning as the potential oncogene [86, 87].
TET1 functions as an important oncoprotein in acute myeloid leukemia (AML) as evidenced by 
the high level expression of TET1 in AML, indicating that efficient inhibition of TET1 expres-
sion could serve as a powerful strategy for AML therapy. Drug screening led to identification 
of two compounds NSC-370284 and its structure analogue UC-514321, which repress TET1 
transcription by targeting directly to target STAT3/5, TET1 transcriptional activators, suggest-
ing the potential of the compounds targeting the STAT/TET1 for efficient therapy of AML [74].
Full length TET1 (TET1FL) has a CXXC domain that binds to unmethylated CpG islands 
(CGIs), allowing TET1 to protect CGIs from aberrant methylation and limiting its ability to 
regulate genes outside of CGIs. An isoform of TET1 (TET1ALT) without CXXC domain but 
still with catalytic domain is repressed in ES cells while it is activated in embryonic and adult 
tissues in contrast to TET1FL’s expression in ESCs and repression in adult tissues. TET1ALT 
aberrant activation is detected in breast cancer, uterine and ovarian cancer, and glioblastoma, 
leading to worse overall survival in these types of cancers. As for the pathogenesis mediated 
by the TET1ALT isoform, a predominantly activated isoform of TET1 in cancer cells does 
not protect from CGI methylation but likely mediates dynamic site-specific demethylation 
outside of CGIs.
3.1.2. Hypoxia induced promotion of TET1 expression
Enhanced expression of TET1 by hypoxia induction has been reported to upregulate cancer 
cell migration, invasion, and proliferation via the HIF1α signaling pathway in JEG3 cells [100], 
suggesting the oncogenic function of TET1 under hypoxia condition.
3.1.3. Overexpression of Tet1 mRNA 3’UTRs leads to sequestration of miRNAs, which 
target the oncogenic transcripts as well, leading to miRNA deficiency to target the oncogenic 
transcript
Transcription levels of TETs were significantly elevated while the protein levels were not in 
gastric cancer (GC) tissues compared to the adjacent normal tissues, suggesting the essential 
role(s) of the endogenous TET transcripts in gastric carcinogenesis and prognosis. Further 
study showed that overexpression of 5’UTRs, CDs, and 3’UTRs contributed to varied effects 
in a way that overexpression of TET 3’UTRS promoted GC growth and proliferation. Given 
that miR-26 targets 3’UTRs of both TET1 and EZH2 mRNAs, overexpression of TET members 
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Figure 3. TET1 functions as a tumor suppressor. (A) In normal cells, TET1 expression is maintained at a regular level. 
The TET1 is recruited to the methylated promoter area of the tumor suppressor genes for demethylation so that the 
tumor suppressor could be expressed at the normal levels. (B) Due to mutation of the Tet1 genes or some other factors, 
Tet1 expression silenced, leading to silencing of the suppressor genes and activation of the oncogenes such as Ezh2. 
Expression of the oncoproteins initiates the tumorigenesis or enhances cancer cell growth and metastasis.
mRNA sequestrates miR-26 competitively and leads to release of the miR-26 mediated repres-
sion of EZH2. Thus, activation of EZH2 expression facilitates gastric carcinogenesis and pro-
gression [87] (Figure 2).
3.2. TET1 serves as a tumor suppressor
The pathogenic contributions the TET members made in various human cancers by functioning 
as tumor suppressors or promoters have been proven to be versatile. The hypermethylation-
based transcriptional silencing of TET1 is frequently detected in non-Hodgkin B cell lymphoma 
(B-NHL), suggesting TET1 as a tumor suppressor of hematopoietic malignancy [91]. Similarly, 
TET1 is downregulated upon NF-κB activation in multiple cancers including basal-like breast 
cancer (BLBC), melanoma, lung, and thyroid cancers, demonstrating that TET1 is the tumor 
suppressor that relies on involvement of the immune system [92].
3.2.1. TET1 methylation-mediated activation of tumor suppressor genes
It is acknowledged that 5hmC depletion initiates carcinogenesis caused by either TET1 expres-
sion repression or aberrant localization. Significantly lower 5-hmC and TET1 expression level 
and subcellular mislocalization in gastric cancer tissues demonstrate the crucial role of TET1 
as a cancer repressor [97] (Figure 3).
In the tested epithelial ovarian cancer (EOC), undetected TET1 expression suggests that the 
consequence of TET1 repression induces the tumorigenesis, in accordance with the inhibition 
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of colony formation, cell migration, and invasion by ectopic expression of TET1 in SKOV3 and 
OVCAR3 cells. The potential mechanism is the TET1 conferred demethylation and the conse-
quent activation of the expression of two key proteins SFRP2 and DKK1 in the canonical Wnt/β-
catenin signaling pathway, associated with inhibition of EMT and metastasis [101].
TET1 is identified as a key tumor suppressor player in ovarian cancer cell lines as well by 
demethylating a CpG site within the Ras association domain family member 5 (RASSF5) 
promoter to enhance expression of the RASSF5, leading to the growth inhibition of ovarian 
cancer cells [102].
More evidences show that EGFR-mediated TET1 repression induces silencing of tumor sup-
pressors in cancer cells such as lung adenocarcinomas and glioblastomas. If only the oncogenic 
EGFR expression is inhibited, TET1 could bind to promoters of the tumor suppressors to activate 
their expression via DNA demethylation. TET1 overexpression inhibits lung and glioblastoma 
tumor growth, and vice versa, in agreement with the significant decrease in TET1 expression 
or TET1 cytoplasmic localization in the majority of lung cancer samples. Thus, it is plausible 
to speculate that TET1 may serve as the therapeutic target for oncogenic EGFR-induced lung 
cancers and glioblastomas [93]. However, Lai et al. could not draw the same conclusion in 
human NSCLC patient samples. They did not detect the EGFR-mediated TET1 silencing, but 
rather observed the significant elevation of the TET1 expression levels in patient samples with 
EGFR mutations, suggesting the inconclusiveness in EGFR-mediated TET1 silencing among 
the cellular and animal models and human lung cancer patients [94].
Eicosapentaenoic acid (EPA), one of the major polyunsaturated fatty acids, could enhance 
the formation of PPARγ-RXRα-TET1 to recruit TET1 to a hypermethylated CpG island on the 
p21 gene for rapid demethylation and consequent expression of p21Waf1/Cip1, leading to 
inhibition of cancer cell-cycle progression in hepatocarcinoma cells. This suggests the bridge 
requirement for TET1 exerting the anti-tumor function and potential of EPA for solid tumor 
therapy such as live cancer [97].
3.2.2. TET1 silencing and loss of 5-hmC induces initiation of tumors
Loss of 5-hydroxymethylcytosine (5 hmC) caused by TET1 dysfunction could induce tumor 
initiation and enhance malignancy by promoting cancer cell growth, migration, and invasion 
in DLD1 colon cancer cells mediated by EZH2 [96]. With loss of TET1, EZH2 repression is 
released, but H3K27 demethylase UTX-1 expression is repressed, enhancing histone H3K27 
tri-methylation and consequently repressing the target gene E-cadherin (DH1). Accordingly, 
even at the condition of TET1 deficiency, either the H3K27 demethylase UTX-1 overexpres-
sion or EZH2 depletion both could enhance H3K27 demethylation at CDH1 promoter, 
thereby impeding EMT and tumor invasion. Likewise, either EZH2 overexpression or UTX-1 
depletion both could promote EMT and tumor metastasis in DLD1 cells. Thus, these results 
elucidate regulation interplay among TET1, E-cadherin, and EZH2 and indicate the critical 
mediator role the EZH2 plays in the E-cadherin repression and tumor progression [95].
3.2.3. miRNA-mediated repression of TET1 expression
Some miRNAs are identified to be involved in regulation of cancer progression or repres-
sion, and one of the mechanisms refers to the oncogenic miRNA-mediated TET1 repression 
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and the consequent loss of 5-hmC. Indeed, miR-21-5p has been confirmed to target Tet1 in 
colorectal cancer (CRC), serving as a biomarker for diagnostics and prognostics in CRC [98]. 
Similarly, miR-4284 directly targeting Tet1 mRNA downregulates TET1 levels of both mRNA 
and protein in human gastric cancer SGC-7901 cells, and thus serves as an oncogenic marker 
[99], suggesting that miR-4284 could provide a potential target for gastric cancer therapy.
3.2.4. Dual function of miRNA by interaction with Tet mRNA 3’UTRs
Some miRNAs are reported to function as both a suppressor and a promoter in some cancers 
such as miR29b in breast cancer (BC) cells by regulation of BC cell proliferation, metastasis, 
and epithelial-mesenchymal transition (EMT). Significantly decreased expression of miR-29b 
in BC samples and cell lines suggests the role of TET1 as a BC suppressor. However, miR-29b 
overexpression promotes cell proliferation, colony formation, migration, and EMT, indicat-
ing that miR-29b functions as a BC promoter [103]. In vitro assay TET1 has been identified 
as one of the miR-29b targets, and it turns out that overexpression of miR29b leads to TET1 
downregulation-mediated promotion of proliferation, colony formation, invasion, and EMT 
in GC cells such as MDA-MB-231 and MCF-7. Further study showed that the TET1-mediated 
suppression of the BC attributed to TET1 conferred disruption of ZEB2 expression by binding 
to the promoter of ZEB2. While the miR-29b/TET1/ZEB2 pathway offers understanding for 
the mechanism of miR-29b and TET1-mediated BC promotion, the suppression mechanism 
for TET1 remains to be elusive in GC [104].
4. Concluding remarks
In the past decades, particularly recent years, significant achievements have been made in 
epigenetic study particularly 5-mC and its derivatives such as 5-hmC, 5-fC, and 5-caC, in 
understanding the generation, dynamic alteration, machinery, distribution, and biological 
functions and connection between the modifications and the pathogenesis of diseases such as 
neurological disorders and cancers. However, a large number of unknown epigenetic events 
related to pathogenesis of many diseases particularly cancers remain to be elusive. Although 
the individual members of the methyltransferase complexes (writer) for cytosine modifica-
tions have been characterized, their coordination in conducting the methylation in response 
to tumorigenesis has not yet been comprehensively investigated. Similarly, the functional 
study on the TET proteins (the erasers for methylation) stays only at the conversion of 5-mC 
to 5-hmC, identification of the targeting miRNAs, and identification of serving as tumor sup-
pressors or promoters by several known mechanisms. However, it is logical to speculate that 
as such huge protein molecules, TET proteins may have much more unidentified functions. 
Further study on the unknown functions will provide essential information for dissecting 
the cancer pathogenesis. First, only limited information is available for the physical interac-
tion components of the TETs; identification of the TET interaction proteins may help us better 
understand how and where the TETs are recruited to function as demethylase to maintain 
the dynamic balance of 5-mC/5-hmC and the chromatin remodeling. Then, identification of 
other functions of TETs other than demethylase will be of importance. Given that the 5-hmC 
is not so much serving an intermediate of demethylation as the important dynamic 5-hmC 
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landscape, it is essential to investigate how the epigenetic information stored in the land-
scape is transformed into the biological effect. To this end, for identification of the readers 
of the 5-hmC modification, the specific 5-hmC binding proteins might be the prerequisite. A 
better understanding the functions of methyltransferase complex for cytosine methylation, 
TETs for demethylation of 5-mC and interaction protein components as well as the other 
known functions, and the specific readers of the 5-hmC marker could identify some epigen-
etic components for therapeutic targets for treatments of cancers and other diseases such as 
neurological disorders.
It has been reported that Tet1 alternative splicing forms have distinct functions [74]. However, 
the information regarding the Tet1 alternative splicing is still limited. Further alternative splic-
ing study may identify more unknown functions conferred by the different isoforms which 
may bear the potential for therapeutic targets.
Additionally, the chemical biology approach based on further identification of small molecule 
compounds that target the 5-mC/5-hmC machineries or the signaling pathways in which 
5-mC/5-hmC involved could help explore therapeutic targets for some stubborn diseases such 
as cancers and neurological diseases.
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